Propanc Biopharma Executes 25-for-1 Reverse Split, Lifts Share Price to $2.02
PPCB•Propanc Biopharma implemented a 25-for-1 reverse stock split reducing outstanding shares from 57 million to 2.3 million to meet Nasdaq listing requirements. Post-split shares are trading at $2.02, reflecting an 18.5% intraday gain and a market capitalization of approximately $1.81 million.
1. Details of Reverse Stock Split
On May 18, 2026, Propanc Biopharma completed a 25-for-1 reverse stock split, consolidating every 25 existing shares into one new share. This action reduced the total outstanding common shares from approximately 57 million to about 2.3 million.
2. Impact on Share Price and Market Cap
Following the split, the stock opened at $2.02, up 18.5% for the day, with trading ranging between $1.56 and $2.29 and volume exceeding 236,700 shares. The company’s market capitalization now stands at roughly $1.81 million.
3. Context and Listing Requirements
The reverse split was undertaken to meet Nasdaq’s minimum bid price requirement and maintain the company’s listing status. This corporate action is intended to support future growth initiatives and improve investor perceptions of the stock’s valuation.
